ReviewBioImpacts : BI2014
Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer.
Review in BioImpacts : BI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- Hyaluronic Acid-Targeted Niosomes for Effective Breast Cancer Chemostarvation Therapy.ACS omega · 2024Article
- Targeted delivery of silibinin via magnetic niosomal nanoparticles: potential application in treatment of colon cancer cells.Frontiers in pharmacology · 2023Article
- Nanoencapsulation ofBioImpacts : BI · 2022Article
- Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.Cellular and molecular life sciences : CMLS · 2020Review
- FMSP-Nanoparticles Induced Cell Death on Human Breast Adenocarcinoma Cell Line (MCF-7 Cells): Morphometric Analysis.Biomolecules · 2018Article
- Microfluidic paper-based analytical devices (µPADs) for fast and ultrasensitive sensing of biomarkers and monitoring of diseases.BioImpacts : BI · 2018Article
- Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells.BioImpacts : BI · 2018Article
- Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.International journal of molecular sciences · 2017Review
- Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy.BioImpacts : BI · 2017Review
- Perspective highlights on biodegradable polymeric nanosystems for targeted therapy of solid tumors.BioImpacts : BI · 2017Review
- Radiolabeled theranostics: magnetic and gold nanoparticles.BioImpacts : BI · 2016Review
- Nuclear molecular imaging with nanoparticles: radiochemistry, applications and translation.The British journal of radiology · 2015Review
- Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.Journal of nanobiotechnology · 2015Article
- Network of nanomedicine researches: impact of Iranian scientists.BioImpacts : BI · 2015Article
- A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination.BioImpacts : BI · 2015Article
- A Novel Exploration of a Combination of Gambogic Acid with TiO₂ Nanofibers: The Photodynamic Effect for HepG2 Cell Proliferation.Materials (Basel, Switzerland) · 2014Article
- Molecular imaging for theranostics in gastroenterology: one stone to kill two birds.Clinical endoscopy · 2014Review
- Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.International journal of nanomedicine · 2014Article
- Impacts of quantum dots in molecular detection and bioimaging of cancer.BioImpacts : BI · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo date, a growing number of advanced anticancer nanomedicines (e.g., Doxil(®), Lipoxal(®), DepoCyte(®)) have entered into different phases of clinical trials. However, most of these medicaments fail to differentiate between diseased and normal cells. They also do not have capability of real time monitoring of disease status trough on-demand imaging/sensing of target molecule(s). Multifunctional nanomedicines and theranostics can resolve such limitations, while formulation of these advanced seamless systems appear to involve various sophisticated process, exploiting several bioconjugations.
methodsRecent works upon multifunctional nanomedicines for simultaneous imaging and therapy of cancer have been systematically reviewed, focusing on surface modification and application of advanced nanobiomaterials.
resultsUltimate therapy of malignancies, as complex systems, demands implementation of seamless nanosystems (NSs) that can specifically target the cancerous cells and smartly deliver the anticancer agent(s) into the desired target site. Engineering of such NSs requires in-situ coordination of various technologies (e.g., synthesis, surface modification and bioconjugation) in order to achieve improved pharmacokinetics and pharmacodynamics outcomes.
conclusionSeamless multimodal NSs have potential to simultaneously target and monitor the tumor cells through homing and imaging/sensing devices and deliver the therapeutic agents. However, to achieve superior pharmacokinetics with maximal efficacy and minimal side effects, these advanced NSs need to become much more intelligent to sense the disease condition and liberate therapeutics on demand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.